$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000119312514062565 Filed on February 21, 2014

Income Statement

Concept	2013 Q4	2012 Q4	2012 Q3
Revenue	$3.063B	$2.478B	$1.946B
YoY Change	23.62%	49.1%	10.7%
Cost Of Revenue	$2.128B	$1.708B	$1.327B
YoY Change	24.61%	46.34%	11.58%
Gross Profit	$935.4M	$770.4M	$618.5M
YoY Change	21.42%	55.57%	8.85%
Gross Profit Margin	30.54%	31.09%	31.78%
Selling, General & Admin	$320.0M	$274.6M	$199.3M
YoY Change	16.53%	183.68%	8.02%
% of Gross Profit	34.21%	35.64%	32.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$138.7M	$109.5M	$80.60M
YoY Change	26.67%	50.0%	18.88%
% of Gross Profit	14.83%	14.21%	13.03%
Operating Expenses	$459.5M	$383.9M	$279.4M
YoY Change	19.69%	129.47%	10.83%
Operating Profit	$484.2M	$388.1M	$340.9M
YoY Change	24.77%	17.69%	7.06%
Interest Expense	-$99.30M	-$98.80M	-$67.40M
YoY Change	0.51%	65.77%	15.81%
% of Operating Profit	-20.51%	-25.46%	-19.77%
Other Income/Expense, Net	$3.500M	$1.000M	$819.0K
YoY Change	250.0%	25.0%	2.38%
Pretax Income	$380.0M	$282.2M	$271.2M
YoY Change	34.68%	4.98%	4.98%
Income Tax	$135.7M	$97.90M	$98.65M
% Of Pretax Income	35.71%	34.7%	36.37%
Net Earnings	$212.3M	$155.8M	$144.7M
YoY Change	36.22%	5.21%	6.91%
Net Earnings / Revenue	6.93%	6.29%	7.44%
Basic Earnings Per Share	$1.01	$0.77	$0.76
Diluted Earnings Per Share	$0.99	$0.75	$0.75
COMMON SHARES
Basic Shares Outstanding	212.7M shares	95.40M shares	190.0M shares
Diluted Shares Outstanding			193.3M shares

Balance Sheet

Concept	2013 Q4	2012 Q4	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$971.3M	$541.0M	$388.0M
YoY Change	79.53%	31.63%	-31.45%
Cash & Equivalents	$946.2M	$533.7M	$382.2M
Short-Term Investments	$25.02M	$7.000M	$6.000M
Other Short-Term Assets	$176.4M	$201.6M	$46.99M
YoY Change	-12.48%	308.46%	-85.5%
Inventory	$88.81M	$78.13M	$78.32M
Prepaid Expenses	$93.88M	$75.85M
Receivables	$1.485B	$1.424B	$1.248B
Other Receivables	$349.1M	$321.0M	$241.0M
Total Short-Term Assets	$3.472B	$2.887B	$2.326B
YoY Change	20.27%	25.89%	-1.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.189B	$1.872B	$1.655B
YoY Change	16.93%	30.69%	23.85%
Goodwill	$9.213B	$8.953B	$5.325B
YoY Change	2.91%	80.97%
Intangibles	$2.024B	$2.128B	$177.5M
YoY Change	-4.87%	1234.32%
Long-Term Investments	$120.0M	$94.00M	$42.00M
YoY Change	27.66%	154.05%	7.69%
Other Assets	$79.60M	$79.85M	$30.56M
YoY Change	-0.32%	133.28%	-4.51%
Total Long-Term Assets	$13.63B	$13.13B	$8.498B
YoY Change	3.8%	98.58%	34.11%
TOTAL ASSETS
Total Short-Term Assets	$3.472B	$2.887B	$2.326B
Total Long-Term Assets	$13.63B	$13.13B	$8.498B
Total Assets	$17.10B	$16.01B	$10.82B
YoY Change	6.77%	79.86%	24.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$435.5M	$414.1M	$272.6M
YoY Change	5.15%	42.98%	5.26%
Accrued Expenses	$772.0M	$567.0M	$529.0M
YoY Change	36.16%	-7.95%	14.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$274.7M	$228.0M	$117.8M
YoY Change	20.48%	161.03%	43.68%
Total Short-Term Liabilities	$2.462B	$2.016B	$1.337B
YoY Change	22.1%	73.12%	10.85%
LONG-TERM LIABILITIES
Long-Term Debt	$8.141B	$8.327B	$5.621B
YoY Change	-2.23%	88.49%	27.25%
Other Long-Term Liabilities	$380.3M	$443.7M	$145.2M
YoY Change	-14.29%	236.15%	-6.89%
Total Long-Term Liabilities	$380.3M	$443.7M	$5.766B
YoY Change	-14.29%	-90.25%	26.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.462B	$2.016B	$1.337B
Total Long-Term Liabilities	$380.3M	$443.7M	$5.766B
Total Liabilities	$11.80B	$11.52B	$7.604B
YoY Change	2.42%	87.04%	13.37%
SHAREHOLDERS EQUITY
Retained Earnings	$3.364B	$3.732B	$3.576B
YoY Change	-9.86%	16.77%
Common Stock	$213.0K	$270.0K	$135.0K
YoY Change	-21.11%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$1.162B	$1.564B
YoY Change		-28.77%
Treasury Stock Shares	0.000 shares	58.73M shares	39.52M shares
Shareholders Equity	$4.432B	$3.763B	$2.537B
YoY Change
Total Liabilities & Shareholders Equity	$17.10B	$16.01B	$10.82B
YoY Change	6.77%	79.86%	24.32%

Cashflow Statement

Concept	2013 Q4	2012 Q4	2012 Q3
OPERATING ACTIVITIES
Net Income	$212.3M	$155.8M	$144.7M
YoY Change	36.22%	5.21%	6.91%
Depreciation, Depletion And Amortization	$138.7M	$109.5M	$80.60M
YoY Change	26.67%	50.0%	18.88%
Cash From Operating Activities	$354.1M	$200.2M	$366.6M
YoY Change	76.87%	32.93%	-25.97%
INVESTING ACTIVITIES
Capital Expenditures	-$218.1M	-$171.2M	-$128.4M
YoY Change	27.39%	15.44%	32.37%
Acquisitions
YoY Change
Other Investing Activities	-$81.70M	-$3.875B	-$71.10M
YoY Change	-97.89%	3183.47%	-90.23%
Cash From Investing Activities	-$299.8M	-$4.046B	-$199.6M
YoY Change	-92.59%	1419.8%	-75.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-78.80M	3.998B	-58.50M
YoY Change	-101.97%	-12632.6%	-141.61%
NET CHANGE
Cash From Operating Activities	354.1M	200.2M	366.6M
Cash From Investing Activities	-299.8M	-4.046B	-199.6M
Cash From Financing Activities	-78.80M	3.998B	-58.50M
Net Change In Cash	-24.50M	152.4M	108.5M
YoY Change	-116.08%	-203.32%	-157.53%
FREE CASH FLOW
Cash From Operating Activities	$354.1M	$200.2M	$366.6M
Capital Expenditures	-$218.1M	-$171.2M	-$128.4M
Free Cash Flow	$572.2M	$371.4M	$495.0M
YoY Change	54.07%	24.26%	-16.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	dei	Entity Public Float EntityPublicFloat	13800000000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393752000
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	213200000	shares
CY2013Q2	dei	Entity Public Float EntityPublicFloat	12800000000
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	212500000	shares
CY2011Q3	dva	Number Of Centers Sold NumberOfCentersSold	28	Entity
CY2011Q4	dva	Number Of Centers Sold NumberOfCentersSold	2	Entity
CY2012Q4	dva	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	3000000000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	860117000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8943000
CY2011Q4	us-gaap	Goodwill Goodwill	4946976000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	269724566	shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	58727416	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	210997150	shares
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	44884000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	78073000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2016425000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15297000
CY2012Q4	us-gaap	Senior Notes SeniorNotes	2800000000
CY2012Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	163520000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	67546000
CY2012Q4	us-gaap	Investments Investments	21123000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	566911000
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3916925000
CY2012Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	10780000
CY2012Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1522183000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1522183000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58530000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1208665000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	414143000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12585000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	443743000
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	233042000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3763137000
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	12073000
CY2012Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	186374000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3731835000
CY2012Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	17976000
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	895634000
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8581121000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	245122000
CY2012Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	142244000
CY2012Q4	us-gaap	Minority Interest MinorityInterest	153788000
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	698480000
CY2012Q4	us-gaap	Liabilities Of Assets Held For Sale LiabilitiesOfAssetsHeldForSale	18440000
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	96594000
CY2012Q4	us-gaap	Liabilities Liabilities	11517016000
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	580692000
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	563365000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	304323000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	270000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16014633000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	715657000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79854000
CY2012Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	460011000
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	75853000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	103458000
CY2012Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	1486160000
CY2012Q4	us-gaap	Land Land	35633000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	516709000
CY2012Q4	us-gaap	Goodwill Goodwill	8952750000
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	52345000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1494676000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2128118000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	231500000
CY2012Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	13985000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1424303000
CY2012Q4	us-gaap	Inventory Net InventoryNet	78126000
CY2012Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	762000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	504124000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3394553000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	324147000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1577976000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	55488000
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1162336000
CY2012Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	174345000
CY2012Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	35150000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1872370000
CY2012Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	9574000
CY2012Q4	us-gaap	Assets Assets	16014633000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	533748000
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	7138000
CY2012Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	148881000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-391510000
CY2012Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	121176000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	201572000
CY2012Q4	us-gaap	Other Receivables OtherReceivables	265671000
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	137387000
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	21545000
CY2012Q4	us-gaap	Other Assets Held For Sale Current OtherAssetsHeldForSaleCurrent	51547000
CY2012Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2432441000
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	59341000
CY2012Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	170494000
CY2012Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	92667
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2887050000
CY2012Q4	dva	Medical Expense Payable MedicalExpensePayable	238964000
CY2012Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	606000
CY2012Q4	dva	Long Term Debt And Capital Lease Obligations Noncurrent LongTermDebtAndCapitalLeaseObligationsNoncurrent	8326534000
CY2012Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	39698000
CY2012Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	292042000
CY2012Q4	dva	Other Current Assets Other OtherCurrentAssetsOther	3250000
CY2012Q4	dva	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	304323000
CY2012Q4	dva	Intangible Lease Liabilities IntangibleLeaseLiabilities	14585000
CY2012Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	29242000
CY2012Q4	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	14657000
CY2012Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	5938000
CY2012Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	126263000
CY2012Q4	dva	Percentage Of Accounts Receivable Six Months Or More Past Due PercentageOfAccountsReceivableSixMonthsOrMorePastDue	0.17	pure
CY2012Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	69527000
CY2012Q4	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	15185000
CY2012Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	928999000
CY2012Q4	dva	Alliance And Product Supply Agreement Gross AllianceAndProductSupplyAgreementGross	68200000
CY2012Q4	dva	Amortized Intangible Liabilities Accumulated Amortization AmortizedIntangibleLiabilitiesAccumulatedAmortization	53543000
CY2012Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9500591000
CY2012Q4	dva	Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments	2146000
CY2012Q4	dva	Carrying Amount Of Longterm Debt Net Of Unamortized Discount Or Premium Current And Noncurrent CarryingAmountOfLongtermDebtNetOfUnamortizedDiscountOrPremiumCurrentAndNoncurrent	8559576000
CY2012Q4	dva	Provider Network And Practice Management Tools Gross ProviderNetworkAndPracticeManagementToolsGross	184264000
CY2012Q4	dva	Funds On Deposit With Third Parties FundsOnDepositWithThirdParties	70922000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	213163248	shares
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	12956094	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	31.98
CY2013Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	45.44
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3539501	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0486	pure
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	213163248	shares
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	45662000
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	910263000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	221498000
CY2013Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	323800000
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	33758000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	84882000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	360457000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2462049000
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2645000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	818343000
CY2013Q4	us-gaap	Senior Notes SeniorNotes	2800000000
CY2013Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	169480000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	60538000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	603013000
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4605541000
CY2013Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5462000
CY2013Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1778259000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1778259000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	15051000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	96167000
CY2013Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	26779000
CY2013Q4	us-gaap	Other Commitment OtherCommitment	3000000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1070922000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2359104000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	435465000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	15205000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	283783000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13860000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	371010000
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	274697000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	4432479000
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	274697000
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10742000
CY2013Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	210008000
CY2013Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	350000000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3363989000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	15610000
CY2013Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	18366000
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1013576000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	339667000
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1897554000
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8433603000
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	237143000
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6577000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	145670000
CY2013Q4	us-gaap	Minority Interest MinorityInterest	173062000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	15060000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	242532000
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	798106000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	152751000
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	806339000
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	845831000
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	152751000
CY2013Q4	us-gaap	Liabilities Liabilities	11796036000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	314322000
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	697300000
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	464422000
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	483773000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	213000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17098877000
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	812419000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	14902000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79598000
CY2013Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	495475000
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93877000
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96212000
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	68747000
CY2013Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	1503426000
CY2013Q4	us-gaap	Land Land	34960000
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	624458000
CY2013Q4	us-gaap	Goodwill Goodwill	9212974000
CY2013Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10315000
CY2013Q4	us-gaap	Investments Investments	25022000
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1749632000
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2024373000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	258562000
CY2013Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	18221000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1485163000
CY2013Q4	us-gaap	Inventory Net InventoryNet	88805000
CY2013Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	22932000
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	610598000
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3967670000
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	409441000
CY2013Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	502655000
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1832221000
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	66839000
CY2013Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	199841000
CY2013Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	40686000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2189411000
CY2013Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	8889000
CY2013Q4	us-gaap	Assets Assets	17098877000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	946249000
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	6801000
CY2013Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	157998000
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-402978000
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	111823000
CY2013Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	121872000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	295443000
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	176414000
CY2013Q4	us-gaap	Other Receivables OtherReceivables	349090000
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	89419000
CY2013Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	192859000
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	17675000
CY2013Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2508146000
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	79557000
CY2013Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	170994000
CY2013Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	145615
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3472278000
CY2013Q4	dva	Medical Expense Payable MedicalExpensePayable	287452000
CY2013Q4	dva	Accounts Receivable Months Outstanding AccountsReceivableMonthsOutstanding	P4M
CY2013Q4	dva	Line Of Credit Weighted Average Interest Rate LineOfCreditWeightedAverageInterestRate	0.0418	pure
CY2013Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	2628000
CY2013Q4	dva	Long Term Debt And Capital Lease Obligations Noncurrent LongTermDebtAndCapitalLeaseObligationsNoncurrent	8141231000
CY2013Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	31219000
CY2013Q4	dva	Renewal Option Terms Minimum Additional Period In Years RenewalOptionTermsMinimumAdditionalPeriodInYears	5	Y
CY2013Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	28058000
CY2013Q4	dva	Other Current Assets Other OtherCurrentAssetsOther	3220000
CY2013Q4	dva	Number Of Entities That Third Parties Held Non Controlling Ownership NumberOfEntitiesThatThirdPartiesHeldNonControllingOwnership	300	Entity
CY2013Q4	dva	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	483773000
CY2013Q4	dva	Intangible Lease Liabilities IntangibleLeaseLiabilities	12563000
CY2013Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	63001000
CY2013Q4	dva	Renewal Option Terms Maximum Additional Period In Years RenewalOptionTermsMaximumAdditionalPeriodInYears	10	Y
CY2013Q4	dva	Long Term Debt Maturities Repayments Of Principal In Year Six And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSixAndThereafter	3698919000
CY2013Q4	dva	Legal Loss Contingency LegalLossContingency	397000000
CY2013Q4	dva	Percentage Of Accounts Receivable Six Months Or More Past Due PercentageOfAccountsReceivableSixMonthsOrMorePastDue	0.14	pure
CY2013Q4	dva	Major Facility Lease Terms Maximum Period In Years MajorFacilityLeaseTermsMaximumPeriodInYears	15	Y
CY2013Q4	dva	Major Facility Lease Terms Minimum Period In Years MajorFacilityLeaseTermsMinimumPeriodInYears	5	Y
CY2013Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	67352000
CY2013Q4	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	19421000
CY2013Q4	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00	pure
CY2013Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	21890000
CY2013Q4	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	9327000
CY2013Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	5601000
CY2013Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1040866000
CY2013Q4	dva	Alliance And Product Supply Agreement Gross AllianceAndProductSupplyAgreementGross	68200000
CY2013Q4	dva	Accrued Liabilities Interest Rate Swaps AccruedLiabilitiesInterestRateSwaps	12069000
CY2013Q4	dva	Amortized Intangible Liabilities Accumulated Amortization AmortizedIntangibleLiabilitiesAccumulatedAmortization	58873000
CY2013Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9333987000
CY2013Q4	dva	Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments	5096000
CY2013Q4	dva	Carrying Amount Of Longterm Debt Net Of Unamortized Discount Or Premium Current And Noncurrent CarryingAmountOfLongtermDebtNetOfUnamortizedDiscountOrPremiumCurrentAndNoncurrent	8415928000
CY2013Q4	dva	Provider Network And Practice Management Tools Gross ProviderNetworkAndPracticeManagementToolsGross	184558000
CY2013Q4	dva	Funds On Deposit With Third Parties FundsOnDepositWithThirdParties	79317000
CY2013Q4	dva	Deferred Tax Assets Loss Contingency Reserve DeferredTaxAssetsLossContingencyReserve	139844000
CY2012Q3	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	The 5 3/4% Senior Notes pay interest on February 15 and August 15 of each year, and the first interest payment date was on February 15, 2013.
CY2011Q3	dva	Number Of Centers To Be Divest NumberOfCentersToBeDivest	30	Entity
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.53
CY2011	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-10785000
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.48
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193064220	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009	pure
CY2011	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3748000	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.042	pure
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.355	pure
CY2011	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	42.61
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.003	pure
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1180046000
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.62
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041	pure
CY2011	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.57
CY2011	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	7589372	shares
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4775000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	189316054	shares
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.09
CY2011	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8776000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	400156000
CY2011	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-4756000
CY2011	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	1077442000
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-602000
CY2011	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	37628000
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-18181000
CY2011	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	335000
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	145687000
CY2011	us-gaap	Profit Loss ProfitLoss	573395000
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-13162000
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	553408000
CY2011	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	45133000
CY2011	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	478336000
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	5971000
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	478336000
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-17918000
CY2011	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	6731806000
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2982000
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	20834000
CY2011	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-29049000
CY2011	us-gaap	Interest Paid InterestPaid	236446000
CY2011	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	100653000
CY2011	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	13689000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	916605000
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	88848000
CY2011	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	36267445000
CY2011	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	406367000
CY2011	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	6280306000
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	458014000
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2039000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	1154713000
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	496182000
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	323348000
CY2011	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	591313000
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	38199000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	478001000
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10270000
CY2011	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	6470540000
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19987000
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	18424000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	53438000
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	5577093000
CY2011	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-374843000
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	95394000
CY2011	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	77074000
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	684715000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-247183000
CY2011	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	38199000
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	48718000
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3309000
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	323348000
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	264225000
CY2011	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	606651000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-466365000
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	47695000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	42191000
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	295099
CY2011	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1149000
CY2011	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	5443000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	202733000
CY2011	us-gaap	Interest Expense Debt InterestExpenseDebt	227667000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	325292000
CY2011	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	75183000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-9721000
CY2011	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-8873000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	98235000
CY2011	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	77418000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84400000
CY2011	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	11061000
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	63661000
CY2011	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	9687000
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11316000
CY2011	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	-694000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7140000
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	247966000
CY2011	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	13423000
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	36395105000
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	20834000
CY2011	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	24000000
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21589000
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	244924000
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48718000
CY2011	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-51979000
CY2011	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	-4756000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1399228000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	57000
CY2011	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	95394000
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	4887000
CY2011	dva	Patient Care Costs PatientCareCosts	4633620000
CY2011	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	315725000
CY2011	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	361000
CY2011	dva	Income Loss From Discontinued Operations Per Basic Share IncomeLossFromDiscontinuedOperationsPerBasicShare	-0.09
CY2011	dva	Debt Expense DebtExpense	241090000
CY2011	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	496517000
CY2011	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	190234000
CY2011	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	241090000
CY2011	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	189309000	shares
CY2011	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	7000	shares
CY2011	dva	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations	4022000
CY2011	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	189316000	shares
CY2011	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	496517000
CY2011	dva	Deferred Income Taxes Expense Benefit DeferredIncomeTaxesExpenseBenefit	70801000
CY2011	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	47051000
CY2011	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	193064000	shares
CY2011	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	467216000
CY2011	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	-5330000
CY2011	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	20329000
CY2011	dva	Proceeds From Sale Of Discontinued Operations ProceedsFromSaleOfDiscontinuedOperations	84000000
CY2011	dva	Supplemental Assets Acquired Under Capital Leases SupplementalAssetsAcquiredUnderCapitalLeases	35764000
CY2011	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-3187000
CY2011	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	340000
CY2011	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-354000
CY2011	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	267315000
CY2011	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-53697000
CY2011	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	2398000
CY2011	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	127660000
CY2011	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	21010000
CY2013	dei	Trading Symbol TradingSymbol	DVA
CY2013	dei	Entity Registrant Name EntityRegistrantName	DAVITA HEALTHCARE PARTNERS INC.
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.02
CY2013	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2013	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-4561000
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.95
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214763887	shares
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014	pure
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2631000	shares
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.001	pure
CY2013	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-7008000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.003	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.041	pure
CY2013	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	4.81
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.339	pure
CY2013	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	4.70
CY2013	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0484	pure
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1773341000
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.95
CY2013	us-gaap	Significant Supply Commitment Description SignificantSupplyCommitmentDescription	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038	pure
CY2013	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.89
CY2013	us-gaap	Targeted Or Tracking Stock Corporate Events TargetedOrTrackingStockCorporateEvents	The Company’s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company
CY2013	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-7979000
CY2013	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4194000	shares
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Use of estimates</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time made. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets including goodwill, valuation adjustments, accounting for income taxes, quarterly, annual and long-term variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</font></p> </div>
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	209939364	shares
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2300000
CY2013	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1039000
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
CY2013	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>17.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Contingencies</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</font></p> <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"> <font style="font-family:Times New Roman" size="2"><b><i>Inquiries by the Federal Government and Certain Related Civil Proceedings</i></b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Vainer Private Civil Suit:</u> In December 2008, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company has been in contact with the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC since November 2008 relating to this matter, and has been advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <i>qui tam</i> provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>2010 U.S. Attorney Physician Relationship Investigation</u>: In May 2010, the Company received a subpoena from the OIG’s office in Dallas, Texas. The civil subpoena covers the period from January 2005 to May 2010, and seeks production of a wide range of documents relating to the Company’s dialysis operations, including documents related to, among other things, financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. The Company has been advised by the attorneys conducting this civil investigation that they believe that some or all of the Company’s joint ventures do not comply with the anti-kickback statute and the False Claims Act. The Company disagrees that its joint venture structure generally, which the Company believes is widely used in the dialysis industry and other segments of the healthcare industry substantially in the form that the Company uses it, violates the federal anti-kickback statute or the False Claims Act. As to individual transactions, the Company made significant effort to ensure that its joint venture structures and process complied with the rules, but the Company is talking with the government about addressing its concerns. The focus of this investigation overlaps substantially with the 2011 U.S. Attorney Physician Relationship Investigation described below. The Company has agreed to a framework for a global resolution with the United States Attorney’s Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation of specific terms. The settlement will include the payment of approximately $389,000, entry into a corporate integrity agreement, the appointment of an independent compliance monitor, and the imposition of certain other business restrictions related to a subset of the Company’s joint venture arrangements. Under the terms of the framework for resolution, the Company has agreed to unwind a limited subset of joint ventures that were created through partial divestiture to nephrologists, and agreed not to enter into this type of partial divestiture joint venture with nephrologists in the future. In 2013, the Company accrued an estimated loss contingency reserve of $397,000 related to this matter. The final settlement remains subject to negotiation of specific terms and will continue to require management’s attention and significant legal expense. The Company can make no assurances as to the final outcome.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>2011 U.S. Attorney Physician Relationship Investigation</u>: In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation relates to the Company’s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlaps substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. As noted above, the Company has agreed to a framework for a global resolution with the United States Attorney’s Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General for both the 2010 and the 2011 U.S. Attorney Physician Relationship Investigations. The final settlement remains subject to negotiation of specific terms and will continue to require management’s attention and significant legal expense. The Company can make no assurances as to the final outcome.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>2011 U.S. Attorney Medicaid Investigation:</u> In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company believes this inquiry is civil in nature. The Company does not know the time period or scope. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company is cooperating with the government and is producing the requested documents.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Swoben Private Civil Suit</u>: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the <i>qui tam</i> provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a <i>qui tam</i> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Haverhill Retirement System Shareholder Derivative Civil Suit</u>: On May 17, 2013, Haverhill Retirement System (Haverhill), a shareholder of the Company, filed a shareholder derivative lawsuit in the U.S. District Court for the District of Colorado against the directors of the Company and against the Company, as nominal defendant. The complaint alleges, among other things, that the Company’s directors breached fiduciary duties to the Company relating to the inquiries by the federal government described above, the Vainer <i>qui tam</i> private civil suit described above and the Woodard <i>qui tam</i> private civil suit for which the Company previously announced a settlement in July 2012. On January 7, 2014, the court consolidated the Haverhill action and the Clark action described below and appointed Haverhill lead plaintiff. The consolidated action is captioned <u>In re DaVita HealthCare Partners, Inc. Derivative Litigation</u> and will be referred to as such going forward.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Clark Shareholder Derivative Civil Suit</u>: As the Company previously disclosed, on August 7, 2012, a shareholder derivative lawsuit was filed in the U.S. District Court for the District of Colorado against certain of the Company’s current and former directors and executives and against the Company, as nominal defendant. The complaint alleged, among other things, that such officers and directors breached fiduciary duties to the Company relating to substantially the same matters that are now the subject of the Haverhill shareholder derivative civil suit described above. As the Company also previously disclosed, on October 19, 2012, the court ordered that the Clark case be administratively closed, subject to being reopened upon a showing of good cause by any party. As described above, the court granted Haverhill’s motion consolidating the actions and appointed Haverhill lead plaintiff. The consolidated action is captioned <u>In re DaVita HealthCare Partners, Inc. Derivative Litigation</u> and will be referred to as such going forward.</font></p> <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"> <font style="font-family:Times New Roman" size="2"><i>Other</i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company has reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and the court has preliminarily approved that settlement. The amount of the settlement is not material to the Company’s consolidated financial statements. The Company intends to continue to vigorously defend against the remaining claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company’s consolidated financial statements.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">In October 2007, the Company was contacted by the Attorney General’s Office for the State of Nevada. The Attorney General’s Office informed the Company that it was conducting a civil and criminal investigation of the Company’s operations in Nevada and that the investigation related to the billing of pharmaceuticals by the Company’s dialysis business, including EPO. In February 2008, the Attorney General’s Office informed the Company that the civil and criminal investigation had been discontinued. The Attorney General’s Office further advised the Company that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and that such audits would relate to the issues that were the subject of the investigation. To the Company’s knowledge, no court proceedings have been initiated against the Company at this time. Any negative audit findings could result in a substantial repayment by the Company. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.</font></p> </div>
CY2013	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	34558000
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	617597000
CY2013	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	13375000
CY2013	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	310394000
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	13249000
CY2013	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	1009305000
CY2013	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	209000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6005000
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	646098000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17731000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	1550134000
CY2013	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	1009166000
CY2013	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	358200000
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	341426000
CY2013	us-gaap	Profit Loss ProfitLoss	757201000
CY2013	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-139000
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	769853000
CY2013	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	2987315000
CY2013	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	633446000
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	12445000
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	633446000
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13236000
CY2013	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	2728000
CY2013	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	11764050000
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4787000
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	36197000
CY2013	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	169000
CY2013	us-gaap	Interest Paid InterestPaid	405030000
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1275000
CY2013	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	139326000
CY2013	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3569000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1124978000
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2216000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59640000
CY2013	us-gaap	Goodwill Other Changes GoodwillOtherChanges	8315000
CY2013	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	66724104000
CY2013	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	763086000
CY2013	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	8013649000
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	3752000
CY2013	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11890346000
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	620197000
CY2013	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	743965000
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	46898000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	633446000
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8971000
CY2013	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	8307195000
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	12652000
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	22187000
CY2013	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-56977000
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	10213916000
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-25380000
CY2013	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	271267000
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	381013000
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-967000
CY2013	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	62258000
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-12889000
CY2013	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-84000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	120775000
CY2013	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	33499000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16666000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	66145000
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6695000
CY2013	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	8295000
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	632000
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	160960000
CY2013	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-44984000
CY2013	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	123755000
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	38368000
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1176485000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-482991000
CY2013	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	46898000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	59998000
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4852000
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	528737000
CY2013	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1016140000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	412501000
CY2013	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	1376000
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	68715000
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	424096
CY2013	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	4158000
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	802000
CY2013	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	397000000
CY2013	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	8480000
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	334258000
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	405010000
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16423000
CY2013	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	8918000
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-8941000
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	373107000
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24933000
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	66286097000
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	36197000
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	404737000
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1764000
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	59998000
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	746000
CY2013	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	78817000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-876882000
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	490000
CY2013	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	123755000
CY2013	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6408000
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4900000
CY2013	dva	Patient Care Costs PatientCareCosts	8198377000
CY2013	dva	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-3901000
CY2013	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	389847000
CY2013	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	-1447000
CY2013	dva	Income Loss From Discontinued Operations Per Basic Share IncomeLossFromDiscontinuedOperationsPerBasicShare	0.07
CY2013	dva	Debt Expense DebtExpense	429943000
CY2013	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	620197000
CY2013	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	293546000
CY2013	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	429943000
CY2013	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	212128000	shares
CY2013	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	5000	shares
CY2013	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	209939000	shares
CY2013	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	65041000
CY2013	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	620197000
CY2013	dva	Ownership In Joint Venture OwnershipInJointVenture	0.50	pure
CY2013	dva	Deferred Income Taxes Expense Benefit DeferredIncomeTaxesExpenseBenefit	-14890000
CY2013	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	12152000
CY2013	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	214764000	shares
CY2013	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	628885000
CY2013	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	-5330000
CY2013	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	-31351000
CY2013	dva	Supplemental Assets Acquired Under Capital Leases SupplementalAssetsAcquiredUnderCapitalLeases	60920000
CY2013	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	11149000
CY2013	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	497000
CY2013	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-2872000
CY2013	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	528119000
CY2013	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	108434000
CY2013	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	3696000
CY2013	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-438007000
CY2013	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	36996000
CY2013	dva	Business Combination Contingent Consideration Acquisitions Tax Related Adjustments BusinessCombinationContingentConsiderationAcquisitionsTaxRelatedAdjustments	-2667000
CY2013	dva	Effective Income Tax Rate Reconciliation Contingent Earn Out Adjustments EffectiveIncomeTaxRateReconciliationContingentEarnOutAdjustments	-0.026	pure
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.79
CY2012	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	366000	shares
CY2012	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-19630000
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.74
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	195942160	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011	pure
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3540000	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.042	pure
CY2012	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	4.10
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.359	pure
CY2012	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	4.02
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1100848000
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.79
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.040	pure
CY2012	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.74
CY2012	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-5221000
CY2012	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2616000	shares
CY2012	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	-31853000
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	192035878	shares
CY2012	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	16377000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	550146000
CY2012	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	4294077000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1541000
CY2012	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	7418000
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-219000
CY2012	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	787625000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	322018000
CY2012	us-gaap	Profit Loss ProfitLoss	641237000
CY2012	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-222000
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	645424000
CY2012	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	481336000
CY2012	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	536017000
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	3935000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	536017000
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-222000
CY2012	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	709000
CY2012	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8186280000
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3737000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	62036000
CY2012	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-6204000
CY2012	us-gaap	Interest Paid InterestPaid	257640000
CY2012	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	113504000
CY2012	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	26761000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1001304000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1205000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	47673000
CY2012	us-gaap	Goodwill Other Changes GoodwillOtherChanges	843000
CY2012	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	39343268000
CY2012	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	588260000
CY2012	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	7116684000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2102000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	540204000
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1775000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	1297084000
CY2012	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	787403000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	2524000
CY2012	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	10875475000
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	536236000
CY2012	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	641459000
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	88964000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	536017000
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4052000
CY2012	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	7351902000
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4187000
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	16874000
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43765000
CY2012	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	4051398000
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	6889196000
CY2012	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32509000
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	105220000
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	18476000
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	889879000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3872384000
CY2012	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	88964000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	45384000
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4339000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	341969000
CY2012	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	459611000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	139996000
CY2012	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	14530000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	49178000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	345066
CY2012	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7211000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	123000
CY2012	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	85837000
CY2012	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	2175000
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1941000
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	239232000
CY2012	us-gaap	Interest Expense Debt InterestExpenseDebt	272134000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	359845000
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-786000
CY2012	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3559000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-10130000
CY2012	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	359763000
CY2012	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	103000
CY2012	dva	Debt Expense DebtExpense	288554000
CY2012	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	195942000	shares
CY2012	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-82000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	228698000
CY2012	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-129948000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	40878000
CY2012	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	19029000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	64195000
CY2012	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1664000
CY2012	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4250000000
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6647000
CY2012	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	3000000000
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	6498000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	299810000
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16420000
CY2012	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	43248175000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	62036000
CY2012	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	47489000
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	289070000
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	660000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45384000
CY2012	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	11083000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4832450000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	75000
CY2012	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	105220000
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	8126000
CY2012	dva	Patient Care Costs PatientCareCosts	5583549000
CY2012	dva	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	58442000
CY2012	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	536236000
CY2012	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	235218000
CY2012	dva	Segment Reporting Information Acquisitions Related Transaction Expenses SegmentReportingInformationAcquisitionsRelatedTransactionExpenses	30753000
CY2012	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	299517000
CY2012	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	192396000	shares
CY2012	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	6000	shares
CY2012	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	192036000	shares
CY2012	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	536236000
CY2012	dva	Deferred Income Taxes Expense Benefit DeferredIncomeTaxesExpenseBenefit	70693000
CY2012	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	52457000
CY2012	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	516387000
CY2012	dva	Fees And Expenses Paid FeesAndExpensesPaid	71840000
CY2012	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	-5330000
CY2012	dva	Debt Refinancing Charge DebtRefinancingCharge	10963000
CY2012	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	30390000
CY2012	dva	Supplemental Assets Acquired Under Capital Leases SupplementalAssetsAcquiredUnderCapitalLeases	55813000
CY2012	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-8214000
CY2012	dva	Proceeds From Issuance Of Senior Notes ProceedsFromIssuanceOfSeniorNotes	1250000000
CY2012	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	8000
CY2012	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-3384000
CY2012	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	343908000
CY2012	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-51730000
CY2012	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	2182000
CY2012	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	3904893000
CY2012	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	37395000
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2013Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.08
CY2013Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.08
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13236000
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	61642000
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	166861000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	30164000
CY2013Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2829582000
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.75
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.75
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.73
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-101000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	260540000
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	320882000
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	140120000
CY2012Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1849533000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.51
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.50
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.49
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	352000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	187392000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	247261000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	95337000
CY2012Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1913006000
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.21
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.18
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	412550000
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.18
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.21
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	522020000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	254376000
CY2013Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2871673000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.76
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.76
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.75
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-13000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	271210000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	340885000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	144721000
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1945888000
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.65
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.64
CY2013Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2	pure
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	270766000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	377074000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	136628000
CY2013Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2999586000
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
CY2012Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.77
CY2012Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.76
CY2012Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-460000
CY2012Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	282162000
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	388056000
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	155839000
CY2012Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2477853000
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2013Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.01
CY2013Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.99
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	380020000
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	484179000
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	212278000
CY2013Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3063209000

Files In Submission

Name	View Source	Status
0001193125-14-062565-index-headers.html	Edgar Link	pending
0001193125-14-062565-index.html	Edgar Link	pending
0001193125-14-062565.txt	Edgar Link	pending
0001193125-14-062565-xbrl.zip	Edgar Link	pending
d637385d10k.htm	Edgar Link	pending
d637385dex121.htm	Edgar Link	pending
d637385dex211.htm	Edgar Link	pending
d637385dex231.htm	Edgar Link	pending
d637385dex311.htm	Edgar Link	pending
d637385dex312.htm	Edgar Link	pending
d637385dex321.htm	Edgar Link	pending
d637385dex322.htm	Edgar Link	pending
dva-20131231.xml	Edgar Link	completed
dva-20131231.xsd	Edgar Link	pending
dva-20131231_cal.xml	Edgar Link	unprocessable
dva-20131231_def.xml	Edgar Link	unprocessable
dva-20131231_lab.xml	Edgar Link	unprocessable
dva-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2013 Q4 Form 10-K Financial Statement

#000119312514062565 Filed on February 21, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2013 Q4 Form 10-K Financial Statement

#000119312514062565 Filed on February 21, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva